Fangyoumin Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fangyoumin Feng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hong Li
CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
3 shared publications - Bihan Shen
Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
2 shared publications - Liangxiao Ma
Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences , Shanghai 200031
2 shared publications - Xueliang Li
Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai China
2 shared publications Bihan Shen
CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China
1 shared publicationKunshi Li
CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031
1 shared publication
Latest Publications
- Open Access
- 22 November 2024
- Published by Association for Computing Machinery (ACM)
- p. 1
Dual-view jointly learning improves personalized drug synergy prediction
Motivation: Accurate and robust estimation of the synergistic drug combination is important for precision medicine. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and make complementary contributes to the final accurate prediction of drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample only using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies.
- 22 November 2024
- Published by Association for Computing Machinery (ACM)
- p. 1
Open AccessDual-view jointly learning improves personalized drug synergy prediction
Motivation: Accurate and robust estimation of the synergistic drug combination is important for precision medicine. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and make complementary contributes to the final accurate prediction of drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample only using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies.
- Open Access
- 1 October 2024
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 40 (10)
Dual-view jointly learning improves personalized drug synergy prediction
Motivation: Accurate and robust estimation of the synergistic drug combination is important for medicine precision. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and makes complementary contributes to the final prediction of the drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies. Availability and implementation: Source code and data are available at https://github.com/LiHongCSBLab/JointSyn.
- 1 October 2024
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 40 (10)
Open AccessDual-view jointly learning improves personalized drug synergy prediction
Motivation: Accurate and robust estimation of the synergistic drug combination is important for medicine precision. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and makes complementary contributes to the final prediction of the drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies. Availability and implementation: Source code and data are available at https://github.com/LiHongCSBLab/JointSyn.
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 48 (7) , 540-551
Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine
- 1 July 2021
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 48 (7) , 540-551
Open AccessLarge-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine